Can you explain why the approval of Gocovri is what is 'resulting' in the Phase 2b PD-LID trial? Seems like big competition to me, but I haven't compared the outcomes to date. Or maybe the information gleaned from the Gocovri trial is informing the redesign? That sort of makes sense.